Today's regulatory sweep found nothing for radiology, which is the expected result rather than a thin day. The sweep reads drug-regulator feeds; radiology practice is governed by appropriateness criteria, society standards and dose regulations, none of which appear there. On this desk, guidance is usually the regulatory news.
The substantive document is the 2026 update of the American College of Radiology Appropriateness Criteria for myelopathy. It covers acute, chronic and vascular causes, providing an imaging framework explicitly intended to guide surgical or medical intervention rather than merely to rank modalities.
The methodology is worth understanding because it explains how to read the recommendations. The criteria are reviewed annually by a multidisciplinary panel, using GRADE-adapted principles for evidence assessment and the RAND/UCLA Appropriateness Method to rate procedures for specific clinical scenarios. Crucially, the document states plainly that where peer-reviewed literature is lacking or equivocal, expert opinion becomes the primary evidentiary source. That is honest and it is also a caution: a high appropriateness rating does not always mean strong evidence, and knowing which is which matters when a rating is used to justify or refuse a scan.
- No radiology regulatory action in today's sweep — the usual pattern for this desk
- Covers acute, chronic and vascular myelopathy
- GRADE-adapted evidence assessment with RAND/UCLA appropriateness rating
- Where literature is lacking, expert opinion is the primary source — read ratings accordingly
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for radiology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free